Compare CVS Health Corp (CVS) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Under Armour Inc Class A — how do they compare? CVS Health Corp trades at $104.91 (market cap $135.48B), while Under Armour Inc Class A trades at $6.7 (market cap $2.79B). The key difference: CVS Health Corp is far larger — about 48.6× Under Armour Inc Class A's market cap, and CVS Health Corp pays a 2.51% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| CVS | UA | |
|---|---|---|
Market Cap | $135.48B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $106.18 | $7.88 |
52-Week Low | $58.75 | $3.96 |
Enterprise Value | $202.02B | $4.42B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Under Armour (UA) trades at $6.61 with a neutral daily performance. The stock shows bullish technical signals from moving averages but faces fundamental challenges with negative net income margins (-9.98%) and declining revenue projections for 2026. Recent earnings showed mixed results with a Q1 2026 miss, while analyst sentiment remains divided with 40.3% buy ratings. The company's cash flow trends show significant outflows, with net cash flow negative $361.87 million in 2025.
The outlook remains cautious due to ongoing revenue declines and profitability challenges, though technical strength and institutional buying by investors like Prem Watsa provide some support. Key risks include sustained negative earnings, competitive pressures, and execution of the company's turnaround strategy. The stock presents a speculative opportunity for investors believing in management's premium product focus and inventory discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
